Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic indices of marbofloxacin after intravenous, subcutaneous, and intramuscular administrations in buffalo calves (&lt;10 days old)

Lüders, Carlos; Baroni, E.; Rubio, S.; Lucas, J. J. De; Díaz, Diego C.; Andrés, M. I. San

doi:10.1111/j.1365-2885.2011.01325.x

Cited by 5 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marbofloxacin half‐life values after intravenous and intramuscular dosing (2 mg/kg) were 4.78 and 5.20 h, respectively, which are similar to those described in dairy calves (4.23 and 4.33 h, respectively) (Aliabadi & Lees, ), longer than those in sheep (3.65 and 3.96 h, respectively) (Sidhu et al ., ), but shorter than those in buffalo calves (6.22 and 5.75 h, respectively) (LÜDers et al ., ). However, a longer half‐life (up to 8 h) in dairy calves experimentally infected with M. haemolytica has been reported (Ismail & El‐Kattan, ).…”

Section: Discussionmentioning

confidence: 97%

“…This confirms the T max of 0.51 h in dairy calves reported by Aliabadi and Lees (). Marbofloxacin C max was 1.68 μg/mL, a value near to those described in dairy calves (1.51 μg/mL, 1.84 μg/mL) (Aliabadi & Lees, ; Sidhu et al ., ), higher than those in buffalo calves (1.11 μg/mL) (LÜDers et al ., ) and sheep (0.81 μg/mL) (Sidhu et al ., ).…”

Section: Discussionmentioning

confidence: 99%

“…A similar value (12.84 μg h/mL) was determined after intramuscular injection. These values were higher than previous reported in Holstein‐Friesian calves (10.11 μg h/mL) (Aliabadi & Lees, ), buffalo calves (9.86 μg h/mL) (LÜDers et al ., ) and sheep (4.19 μg h/mL) (Sidhu et al ., ). However, Ismail and El‐Kattan () reported a similar value in healthy dairy calves and higher value in dairy calves experimentally infected with M. haemolytica following intravenous administration, for which the marbofloxacin AUC was 12.00 and 25.54 μg h/mL, respectively.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue‐cage model in yellow cattle

Wang

Yang

et al. 2013

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The fluoroquinolone antimicrobial drug marbofloxacin was administered to yellow cattle intravenously and intramuscularly at a dose of 2 mg/kg of body weight in a two-period crossover study. The pharmacokinetic properties of marbofloxacin in serum, inflamed tissue-cage fluid (exudate), and noninflamed tissue-cage fluid (transudate) were studied by using a tissue-cage model. The in vitro and ex vivo activities of marbofloxacin in serum, exudate, and transudate against a pathogenic strain of Pasteurella multocida (P. multocida) were determined. Integration of in vivo pharmacokinetic data with the in vitro MIC provided mean values for the area under the curve (AUC)/MIC for serum, exudate, and transudate of 155.75, 153.00, and 138.88, respectively, after intravenous dosing and 160.50, 151.00, and 137.63, respectively, after intramuscular dosing. After intramuscular dosing, the maximum concentration/MIC ratios for serum, exudate, and transudate were 21.13, 9.13, and 8.38, respectively. The ex vivo growth inhibition data after intramuscular dosing were fitted to the inhibitory sigmoid Emax equation to provide the values of AUC/MIC required to produce bacteriostasis, bactericidal activity, and elimination of bacteria. The respective values for serum were 17.25, 31.29, and 109.62, and slightly lower values were obtained for transudate and exudate. It is proposed that these findings might be used with MIC50 or MIC90 data to provide a rational approach to the design of dosage schedules which optimize efficacy in respect of bacteriological as well as clinical cures.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue‐cage model in yellow cattle

Wang

Yang

et al. 2013

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…For calves administered marbofloxacin in accordance with regimen 2, blood samples were collected 0, 10, 20, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 28, 32, 36, and 48 hours after the first and second injections as well as 0, 10, 20, 30, and 45 minutes and 1, 1. 5,2,3,4,6,8,10,12,24,28,32,36,48,52,56,60, and 72 hours after the third injection. For calves administered marbofloxacin in accordance with regimen 3, blood samples were collected 0, 10, 20, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours after the first and second injections as well as 0, 10, 20, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 28, 32, 36, 48, 52, 56, 60, and 72 hours after the third injection.…”

Section: Animalsmentioning

confidence: 99%

Comparison of pharmacokinetics of marbofloxacin after subcutaneous administration of various multiple-dose regimens to water buffalo calves (Bubalus bubalis)

Baroni

Rubio²,

Lucas³

et al. 2014

ajvr

Self Cite

View full text Add to dashboard Cite

show abstract

“…The distribution of MBFX within the bronchoalveolar region has been reported in dogs after oral administration [4]. In cattle, only the concentration of MBFX in blood has been reported [2, 3, 11], and no reports were made concerning the concentrations of MBFX within the bronchoalveolar region. The purpose of this study was to elucidate the concentration of MBFX in bronchoalveolar lavage fluid (BALF) after administration of MBFX injections into healthy calves.…”

mentioning

confidence: 99%

Distribution of marbofloxacin in the bronchoalveolar region in healthy calves

Hayashi

Otomaru

Hirata

et al. 2019

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

The purpose of this study was to clarify the distribution of marbofloxacin (MBFX) within the bronchoalveolar region of calves. Four clinically healthy calves were intramuscularly injected with a single dose of MBFX (2 mg/kg). Samples of plasma and bronchoalveolar lavage fluid (BALF) were obtained for each calf at 0 (before administration), 1, 2, 6 and 24 hr after injection of MBFX. The injections and series of sample collections were conducted and repeated again after two weeks. The results show that the MBFX concentrations in the pulmonary epithelial lining fluid (ELF) were significantly higher than that in plasma and in alveolar cells at 2 hr after injection ( P <0.05). For concentrations of MBFX within the ELF, the mean area under the MBFX concentration curve calculated during the 0 to 24 hr timeframe (AUC 0–24 ) was significantly higher than the mean determined from samples collected from the plasma ( P <0.05). These results suggest that intramuscularly injected MBFX was well distributed in the bronchoalveolar region.

show abstract

Pharmacokinetic behavior and pharmacokinetic/pharmacodynamic indices of marbofloxacin after intravenous, subcutaneous, and intramuscular administrations in buffalo calves (<10 days old)

Cited by 5 publications

References 20 publications

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue‐cage model in yellow cattle

Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Pasteurella multocida in a tissue‐cage model in yellow cattle

Comparison of pharmacokinetics of marbofloxacin after subcutaneous administration of various multiple-dose regimens to water buffalo calves (Bubalus bubalis)

Distribution of marbofloxacin in the bronchoalveolar region in healthy calves

Contact Info

Product

Resources

About